Did you mean 9054 02 0?
Displaying drugs 526 - 550 of 1424 in total
PF-06291874
PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus).
Investigational
PF-06260414
PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects).
Investigational
PF-06835919
PF-06835919 is under investigation in clinical trial NCT05463575 (Ketohexokinase Inhibition in NAFLD).
Investigational
MEDI0680
Investigational
Dazukibart
Investigational
NYX-2925
NYX-2925 is under investigation in clinical trial NCT04146896 (Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)).
Investigational
Marstacimab
Marstacimab is a human Monoclonal Antibody Directed Against Tissue Factor Pathway Inhibitor currently being developed by Pfizer for the treatment of hemophilia A and hemophilia B.
Investigational
Pelabresib anhydrous
Investigational
Cavrotolimod
Investigational
Saruparib
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
AP-001
Investigational
Asvasiran
Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Investigational
INS018_055
Investigational
IKT-001Pro
Investigational
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Fordadistrogene movaparvovec
Investigational
MPT-0L055
Investigational
BPR-0L075
Investigational
Brogidirsen
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
Stamulumab
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
BMX-001 free base
Investigational
TAK-075 Free base
Investigational
BMN-045
Experimental
Withdrawn
BMN-044
Experimental
Withdrawn
Displaying drugs 526 - 550 of 1424 in total